TFS Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

TFS Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,518	Closed	-$46K	–	449
2017 Q2	$46K	Sell	14,518 -1,686	-10%	-$5.32K	0.02%	593
2017 Q1	$55K	Sell	16,204 -11,500	-42%	-$32.4K	0.02%	622
2016 Q4	$80K	Buy	+27,704	New	+$98.5K	0.02%	660
2016 Q3	–	Sell	-30,429	Closed	-$91K	–	1069
2016 Q2	$91K	Buy	+30,429	New	+$125K	0.02%	869
2015 Q3	–	Sell	-76,364	Closed	-$1.06M	–	1099
2015 Q2	$1.06M	Buy	+76,364	New	+$1.4M	0.1%	315
2014 Q4	–	Sell	-27,914	Closed	-$355K	–	1213
2014 Q3	$355K	Buy	27,914 +17,582	+170%	+$265K	0.03%	700
2014 Q2	$233K	Buy	+10,332	New	+$187K	0.02%	904

Other funds holding DRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

TFS Capital's DRNA Position: Q3 2017 in Review

TFS Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2017, closing a stake of 14,518 shares — an estimated $46K sold.

TFS Capital first reported a position in DRNA in Q2 2014 and held it in 7 quarters. The position peaked at $1.06M in Q2 2015. 37 funds tracked by Wall St. Rank hold DRNA as of Q3 2017.

TFS Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 14,518 Dicerna Pharmaceuticals, Inc. shares in Q3 2017, an estimated $46K.
TFS Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 7 quarters.
TFS Capital's Dicerna Pharmaceuticals, Inc. position peaked at $1.06M in Q2 2015.
37 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.